• 2019-10
  • 2019-11
  • 2020-07
  • 2020-08
  • 2021-03
  • br Gatfield ER Noble DJ Barnett GC et al Tumour


    5. Gatfield ER, Noble DJ, Barnett GC, et al. Tumour Volume and Dose Influence Outcome after Surgery and High-dose Photon Radiotherapy for Chordoma and Chondrosarcoma of the Skull Base and Spine. Clinical oncology (Royal College of Radiologists (Great Britain)) 2018;30(4):243-53 doi: 10.1016/j.clon.2018.01.002[published Online First: Epub Date] .
    6. Zuckerman SL, Bilsky MH, Laufer I. Chordomas of the Skull Base, Mobile Spine, and Sacrum: An Epidemiologic Investigation of Presentation, Treatment, and
    9. Sanusi OR, Arnaout O, Rahme RJ, Horbinski C, Chandler JP. Surgical Resection And Adjuvant Radiation Therpy In The Treatment Of Skull Base Chordomas. World neurosurgery 2018 doi: 10.1016/j.wneu.2018.02.127[published Online First: Epub Date] .
    11. Meng T, Yin H, Li B, et al. Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single
    Online First: Epub Date] .
    20. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. Journal of clinical oncology : official journal of the American Society of
    22. Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing WY 14643 after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology 2009;20(5):955-60 doi: 10.1093/annonc/mdn723[published Online First: Epub Date] .
    26. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. European journal of surgical
    27. Ruggieri P, Angelini A, Ussia G, Montalti M, Mercuri M. Surgical margins and local control in resection of sacral chordomas. Clinical orthopaedics and
    29. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993;72(3):714-8
    31. Shih AR, Cote GM, Chebib I, et al. Clinicopathologic characteristics of poorly differentiated chordoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 doi: 10.1038/s41379-018-0002-1[published Online First: Epub Date] .
    Figure legend
    Figure 1. Identification of optimal cutoff values of age WY 14643 of diagnosis (A, B) and tumor size (C, D) via X-tile analysis.
    Optimal cutoff values of age were identified as 38, 54, and 66 years based on overall survival. Optimal cutoff values of tumor size were identified as 2.9 cm and 10.0 cm based on overall survival. Histogram and Kaplan-Meier analysis were developed based on sink cutoff values.
    Figure 2. Nomograms to predict 3- and 5-year (A) overall survival (B) cancer-specific survival for patients with chordoma.
    A vertical line can be drawn between each variable and the points scale to acquire the points of each variable. Predicted survival rate was calculated according to the total points by drawing a vertical line from the Total Points scale to the overall survival or cancer-specific survival scale.
    Figure 3. Internal calibration plots of 3-year (A) and 5-year (B) overall survival nomogram calibration curves; 3-year (C) and 5-year (D) cancer-specific survival nomogram calibration curves.
    The cohort was divided into five subgroups with the equal sample size for present internal validation. The dashed line represents an excellent match between actual survival outcome (Y-axis) and nomogram prediction (X-axis). Closer distances between dashed line and points indicate higher prediction accuracy.
    Table 1: Baseline demographic and clinical characteristics of patients with chordoma
    Variables Training cohort Validation cohort
    Total P
    associated joints
    Surgical stage, n, %
    Chemotherapy, n, %
    No significant differences regarding patient age, gender, primary site, tumor size,
    histology, surgical stage, use of surgery, use of chemotherapy and use of radiation
    were found between training and validation cohort.
    Table 2: Univariate cox regression analysis of cancer-specific survival and Overall survival in the training cohort
    Variables Cancer-specific survival
    Overall survival
    Male Reference
    <38 Reference